Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioLight Life SciencesBLLSF 16 Debt-to-EBITDA is -0.04 as of Dec. 2025. GuruFocus rates BLLSF with a GF Score™ of 16/100. The stock has 3 warning signs investors should review. Among 296 Biotechnology companies, BioLight Life Sciences ranks worse than 337837.5% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for BioLight Life Sciences's Debt-to-EBITDA or its related term are showing as below:
BLLSF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.33 Med: -0.07 Max: 0
Current: -0.05
BLLSF's Debt-to-EBITDA is ranked worse than 100% of 296
companies
in the Biotechnology industry
Industry Median: 1.185
vs BLLSF: -0.05
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
BioLight Life Sciences Debt-to-EBITDA Related Terms
BioLight Life Sciences Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for BioLight Life Sciences's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLLSF vs VRTX, REGN, RVMD: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, BioLight Life Sciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioLight Life Sciences Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioLight Life Sciences's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where BioLight Life Sciences's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
BioLight Life Sciences (BLLSF) has a Debt-to-EBITDA of -0.04 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on BioLight Life Sciences. According to the industry distribution chart, BioLight Life Sciences ranks #999999 out of 296 companies in the Biotechnology industry.
Is BioLight Life Sciences' Debt-to-EBITDA too high?
BioLight Life Sciences' current Debt-to-EBITDA is -0.04. Based on the distribution chart, BioLight Life Sciences ranks #999999 out of 296 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BioLight Life Sciences has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does BioLight Life Sciences' Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioLight Life Sciences ranks #999999 out of 296 companies for Debt-to-EBITDA. This places BioLight Life Sciences in the lower half of its industry. The industry median Debt-to-EBITDA is 1.19. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.19, based on 296 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on BioLight Life Sciences. For the Biotechnology industry, the median Debt-to-EBITDA is 1.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioLight Life Sciences's current Debt-to-EBITDA is -0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLight Life Sciences stock overvalued right now?
BioLight Life Sciences (BLLSF) has a current Debt-to-EBITDA of -0.04. The current Debt-to-EBITDA is -0.04. BioLight Life Sciences' overall GF Score™ is 16/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For BioLight Life Sciences (BLLSF), the current Debt-to-EBITDA is -0.04 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioLight Life Sciences Ltd is an emerging ophthalmic company. It is engaged in the discovery, development, and commercialization of products and product candidates which address ophthalmic conditions, including glaucoma, dry eye syndrome and age-related macular degeneration. The firm's products include ioptimate, eye-d technology, and diagnostear. The company has the Eye cluster and the Cancer diagnostics cluster operating segments. It derives the majority of its revenues from the Eye cluster segment.
16GF Score
Get the complete analysis for BLLSF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLLSF has been successfully added to your 
